Takeda, Furiex await FDA approval decision on diabetes drug Nesina

Today we might glimpse the U.S. Food and Drug Administration’s thoughts on approving new type 2 diabetes drugs in a post-Avandia world. Nesina, a Takeda Pharmaceutical (TYO:4502) compound licensed f…
Read the full story: MedCity News